在慢性心力衰竭中优化β-阻塞剂治疗:对患有心房动和没有心房动的患者进行现实研究
Karel Labr1, Jindrich Spinar1, Jiri Parenica2
1First Department of Internal Medicine - Cardioangiology, Faculty of Medicine, Masaryk University, St. Anne's University Hospital, Brno, Czech Republic.
Postgraduate medicine
|December 29, 2025
概括
更高剂量的β-阻塞剂 (BBs) 改善了心力衰竭 (HF) 患者的结果,即使是心房动 (AF) 患者. 这支持在所有HF患者的指导方针导向治疗中升级BBs.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭 (HF) 减少或轻微减少喷射分数往往与心房动 (AF) 共存.
- 这种组合导致预后更差,治疗复杂性增加.
- 贝塔阻断剂 (BBs) 的益处,是HF治疗的基石,在AF患者中并不成熟.
研究的目的:
- 调查慢性心力衰竭 (HF) 患者获得的β-阻断剂 (BB) 剂量和临床结果之间的关联.
- 要确定这种关联在有心房动 (AF) 和没有心房动 (AF) 的患者中是否有所不同.
主要方法:
- 来自FAR NHL注册表的1088名慢性HF患者 (左心室喷射分数<50%) 的分析.
- 患者根据AF的存在进行了分层,并获得了BB剂量 (低,中,高).
- 主要终点:综合所有原因死亡率,急性HF住院,LVAD植入或心脏移植.
主要成果:
- 在34.5%的患者中存在心房动 (AF).
- 较高的BB剂量与初级终点 (HR 0.62;p < 0.001) 的风险显著降低有关.
- 这种关联在患有和没有AF的患者中是一致的.
结论:
- 较高的BB剂量与慢性HF患者的改善结果有关,无论AF状态如何.
- 这些发现支持BBs的上升标配,作为指导方针导向治疗的关键部分.
- 优化的BB疗法即使对具有同时存在AF的HF患者也是有益的.
相关概念视频
Heart Failure Drugs: β-Blockers
727
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
727
Heart Failure V: Medical Management
196
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
196
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
874
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
874
Heart Failure VI: Adjunct Therapies
233
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
233
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.4K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.4K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.5K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.5K


